NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. manufactures and sells wound care products. The company offers hypochlorous acid for use in the cleansing and irrigation of post-surgical wounds, minor burns, and superficial abrasions. It sells its products to its distribution partners in China. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in F… Read more
NovaBay Pharmaceuticals Inc (NBY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.102x
Based on the latest financial reports, NovaBay Pharmaceuticals Inc (NBY) has a cash flow conversion efficiency ratio of -1.102x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.80 Million) by net assets ($1.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NovaBay Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how NovaBay Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NovaBay Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NovaBay Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NETCLASS TECHNOLOGY INC Class A Ordinary Shares
NASDAQ:NTCL
|
0.006x |
|
Aethlon Medical Inc
NASDAQ:AEMD
|
0.000x |
|
Elemental Royalties Corp
OTCQX:ELEMF
|
0.020x |
|
VSBLTY Groupe Technologies Corp
PINK:VSBGF
|
-0.231x |
|
DIAMOND EST.WIN.+SPIRITS
F:4WS0
|
N/A |
|
iMetal Resources Inc.
OTCQB:IMRFF
|
-0.062x |
|
Spadel SA
LSE:0OH1
|
N/A |
|
GENRF
OTCGREY:GENRF
|
-0.112x |
Annual Cash Flow Conversion Efficiency for NovaBay Pharmaceuticals Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of NovaBay Pharmaceuticals Inc from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-129.00K | $-5.18 Million | 40.178x | +3224.87% |
| 2023-12-31 | $3.31 Million | $-4.26 Million | -1.286x | -103.94% |
| 2022-12-31 | $10.55 Million | $-6.65 Million | -0.630x | +30.24% |
| 2021-12-31 | $10.17 Million | $-9.19 Million | -0.904x | -135.80% |
| 2020-12-31 | $12.32 Million | $-4.72 Million | -0.383x | +95.30% |
| 2019-12-31 | $973.00K | $-7.93 Million | -8.149x | -625.04% |
| 2018-12-31 | $4.95 Million | $-5.57 Million | -1.124x | +53.50% |
| 2017-12-31 | $2.59 Million | $-6.27 Million | -2.417x | -41.44% |
| 2016-12-31 | $7.10 Million | $-12.13 Million | -1.709x | -146.94% |
| 2015-12-31 | $-5.10 Million | $-18.56 Million | 3.640x | +144.69% |
| 2014-12-31 | $1.85 Million | $-15.05 Million | -8.147x | -434.94% |
| 2013-12-31 | $8.52 Million | $-12.97 Million | -1.523x | -227.75% |
| 2012-12-31 | $14.05 Million | $-6.53 Million | -0.465x | -38.19% |
| 2011-12-31 | $9.34 Million | $-3.14 Million | -0.336x | -273.93% |
| 2010-12-31 | $10.49 Million | $2.03 Million | 0.193x | +256.55% |
| 2009-12-31 | $13.35 Million | $-1.65 Million | -0.123x | +90.88% |
| 2008-12-31 | $7.34 Million | $-9.94 Million | -1.354x | -209.09% |
| 2007-12-31 | $14.32 Million | $-6.27 Million | -0.438x | -116.74% |
| 2006-12-31 | $1.81 Million | $4.74 Million | 2.617x | +363.45% |
| 2005-12-31 | $3.25 Million | $-3.23 Million | -0.993x | -- |